266 related articles for article (PubMed ID: 22430206)
1. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.
Iida M; Brand TM; Campbell DA; Li C; Wheeler DL
Oncogene; 2013 Feb; 32(6):759-67. PubMed ID: 22430206
[TBL] [Abstract][Full Text] [Related]
2. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
[TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
4. Nuclear EGFR contributes to acquired resistance to cetuximab.
Li C; Iida M; Dunn EF; Ghia AJ; Wheeler DL
Oncogene; 2009 Oct; 28(43):3801-13. PubMed ID: 19684613
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
[TBL] [Abstract][Full Text] [Related]
6. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL
Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198
[TBL] [Abstract][Full Text] [Related]
7. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
8. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
10. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab.
Iida M; Brand TM; Campbell DA; Starr MM; Luthar N; Traynor AM; Wheeler DL
Cancer Biol Ther; 2013 Jun; 14(6):481-91. PubMed ID: 23760490
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
12. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.
Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA
Br J Cancer; 2012 Apr; 106(8):1406-14. PubMed ID: 22491422
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
Li C; Iida M; Dunn EF; Wheeler DL
Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
[TBL] [Abstract][Full Text] [Related]
14. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
15. Differential mitotic activation of endogenous c-Src, c-Yes, and Lyn in HeLa cells.
Kuga T; Nakayama Y; Hoshino M; Higashiyama Y; Obata Y; Matsuda D; Kasahara K; Fukumoto Y; Yamaguchi N
Arch Biochem Biophys; 2007 Oct; 466(1):116-24. PubMed ID: 17692281
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK.
Dittmann K; Mayer C; Kehlbach R; Rodemann HP
Mol Cancer; 2008 Sep; 7():69. PubMed ID: 18789131
[TBL] [Abstract][Full Text] [Related]
17. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.
Sutton P; Borgia JA; Bonomi P; Plate JM
Mol Cancer; 2013 Jul; 12():76. PubMed ID: 23866081
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
Eguchi R; Kubo S; Takeda H; Ohta T; Tabata C; Ogawa H; Nakano T; Fujimori Y
Carcinogenesis; 2012 May; 33(5):969-75. PubMed ID: 22354875
[TBL] [Abstract][Full Text] [Related]
20. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
